Loading…
Chinese pharmaceutical group with a leading position in anesthetic and pain-management drugs, plus broader generics and healthcare businesses.
Chinese pharmaceutical group with a leading position in anesthetic and pain-management drugs, plus broader generics and healthcare businesses.
Sells prescription drugs to hospitals, where its anaesthetics and pain relievers hold a strong position because they are tightly controlled substances that few makers are licensed to produce. Hospital pricing is shaped by China's government-led bulk-purchase tenders, which cut prices in exchange for volume. It also owns a US generic-drug business.
Moat: narrow (regulatory licence, brand). Controlled-substance manufacturing licences for anesthetics are hard to obtain, protecting incumbents.
Headquarters: Wuhan, China · Employees: 17,153
Size Humanwell Healthcare (Group) (600079.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $4.71B, the 537th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥19.51 on 6 Nov 2026.
Performance Over six months the shares gained 3.3%, against +1.8% for the median peer and -16.4% for the China market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue fell 2.5% over the last twelve months (peer median +14.0%); the operating margin is 15.6% (peer median 16.5%).
Valuation It trades at 13.4× forward earnings against a peer median of 31.8× (4th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -10 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.9 points above its cost of capital (5.0% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥24.0B | CN¥23.8B | CN¥25.3B | CN¥24.4B | CN¥22.2B |
| Revenue growth | — | -6% | +4% | +10% | — |
| Gross profit | CN¥11.2B | CN¥10.9B | CN¥10.6B | CN¥10.7B | CN¥9.21B |
| EBITDA | CN¥4.75B | CN¥4.60B | CN¥3.91B | CN¥4.10B | CN¥3.57B |
| Net income | CN¥2.03B | CN¥1.86B | CN¥1.33B | CN¥2.13B | CN¥2.48B |
| Free cash flow | CN¥2.09B | CN¥1.83B | CN¥1.17B | CN¥89.4M | -CN¥621M |
| Capital expenditure | CN¥615M | CN¥733M | CN¥1.02B | CN¥1.96B | CN¥3.11B |
| Total debt | CN¥8.45B | CN¥8.99B | CN¥9.52B | CN¥9.95B | CN¥11.0B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Humanwell Healthcare (Group) 600079.SS | $4.71B | +3% | -3% | 16% | 13.4× | -6.8% |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | $3.47B | +2% | +3% | 19% | 19.6× | -2.2% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $49.7B | -6% | +6% | 27% | 36.4× | 14.9% |
| Haisco Pharmaceutical 002653.SZ | $10.0B | +1% | +42% | 18% | 39.3× | 20.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600079.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.7% | +0.2% | 10th highest of 20 |
| 6-month return | +3.3% | +1.8% | 10th highest of 20 |
| Distance from 52-week high | -10.3% | -30.8% | 4th highest of 21 |
| Revenue growth (TTM) | -2.5% | +14.0% | 3rd lowest of 19 |
| Operating margin | 15.6% | 16.5% | 8th lowest of 19 |
| Forward P/E | 13.4× | 31.8× | 4th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -6.8% | 12.6% | least demanding of 17 |
| Growth delivered (Del g) | +3.0% | +10.9% | 3rd lowest of 17 |
| Hurdle (Req g minus delivered) | -9.8 pp | -0.2 pp | 4th least demanding of 17 |
| ROIC minus cost of capital | +4.9 pp | +4.5 pp | 9th highest of 18 |
| EV / EBITDA | 7.8× | 22.2× | cheapest of 9 |
| Net debt / EBITDA | 0.7× | -0.2× | 4th most indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Humanwell Healthcare (Group) 600079.SS | China | $4.71B | +3% | -3% | 16% | 13.4× | -6.8% | +3.0% |
| Travere Therapeutics TVTX | United States | $4.76B | +16% | +49% | -3% | 16.9× | 16.7% | +19.9% |
| Novast Laboratories 301569.SZ | China | $4.82B | n/a | +3% | 27% | n/a | 42.6% | +3.1% |
| Guangzhou Baiyunshan Pharmaceutical 600332.SS | China | $4.61B | -11% | +1% | 3% | 13.3× | -0.3% | +4.7% |
| Legend Biotech Corp. Sponsored ADR LEGN | United States | $4.53B | -17% | +60% | -4% | 64.5× | n/a | n/a |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.53B | +2% | +12% | 33% | 35.9× | 25.2% | +5.5% |
| Camurus CAMX.ST | Sweden | $4.52B | +47% | 0% | 37% | 48.5× | 10.4% | +46.5% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.47B | +33% | +21% | 16% | 33.9× | 14.9% | +12.7% |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $4.47B | -34% | +227% | 74% | 46.9× | 3.3% | +45.1% |
| Definium Therapeutics DFTX | United States | $4.47B | +51% | n/a | n/a | n/a | n/a | n/a |
| Erasca ERAS | United States | $5.04B | +42% | n/a | n/a | n/a | n/a | n/a |
| Ajanta Pharma AJANTPHARM.NS | India | $4.37B | +7% | +25% | 25% | 32.2× | 23.8% | +13.8% |
| HanmiPharm 128940.KS | South Korea | $4.36B | +2% | +14% | 16% | 16.8× | 5.0% | +7.5% |
| SKBP 326030.KS | South Korea | $5.12B | -11% | +39% | 35% | 21.6× | 0.5% | +93.6% |
| Shenzhen Salubris Pharmaceuticals 002294.SZ | China | $5.18B | -39% | +14% | 11% | 41.6× | 15.5% | +9.7% |
| IPCA Laboratories IPCALAB.NS | India | $5.22B | +24% | +11% | 17% | 32.4× | 17.8% | +12.2% |
| Sumitomo Pharma 4506.T | Japan | $5.23B | +7% | +11% | 10% | 8.3× | 1.4% | -2.6% |
| Beijing TongRenTang 600085.SS | China | $5.27B | -8% | -17% | 8% | 31.2× | 2.7% | +6.2% |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $4.11B | +4% | -13% | 20% | 31.4× | 17.8% | -5.8% |
| Supernus Pharmaceuticals SUPN | United States | $5.43B | -49% | +16% | 45% | 6.7× | 4.2% | +13.9% |
| Shanghai Junshi Biosciences 1877.HK | Hong Kong | $4.08B | -39% | +36% | -14% | n/a | n/a | n/a |